BridgeBio says heart disease therapy Attruby beat Pfizer’s Vyndamax in real world study

Data ReadoutpositiveAttrubyVyndamaxPositive

AI Analysis

BridgeBio announced that its heart disease therapy Attruby demonstrated superior performance compared to Pfizer's Vyndamax in a real world study.

Attruby beat Pfizer's Vyndamax in real world study

Importance:6/10

Sentiment:

0.70

heart diseasereal world datacompetitive comparisonclinical data

Related Companies

Read the original article

Published by Seeking Alpha Healthcare on September 23, 2026 12:25 PM